The research, led by Dong Cui of Henan Provincial Chest Hospital in Zhengzhou together with colleagues at Shanghai Pulmonary Hospital and Tongji University School of Medicine, centers on CYP3A5, an enzyme belonging to the cytochrome P450 family. Cytochrome P450 enzymes are best known for metabolizing drugs in the liver, but in recent years they have emerged as regulators of endothelial cell behavior within tumors. What remained unexplored until now was whether endothelial CYP3A5 plays a role in shaping the immune landscape of lung adenocarcinoma, and whether it could serve as a druggable target for therapies designed to reawaken the immune system against the cancer.

To answer that question, the team deployed an unusually broad methodological arsenal. They began with bioinformatic screening across large public datasets, including The Cancer Genome Atlas and the Genotype-Tissue Expression project, to pinpoint candidate endothelial targets in lung adenocarcinoma. They then layered on single-cell RNA sequencing and spatial transcriptomics, technologies that allow researchers to see which genes are active in individual cells and where those cells sit within the tumor architecture. This dual lens revealed that CYP3A5 is predominantly expressed in the endothelial cells of minimally invasive lung adenocarcinoma, an early stage of the disease, positioning the enzyme at a critical juncture in tumor evolution.

Having identified CYP3A5 as a candidate, the researchers asked what controls it. Through molecular docking, chromatin immunoprecipitation followed by quantitative PCR, DNA pulldown assays, and luciferase reporter experiments, they demonstrated that the transcription factor GATA6 sits upstream of CYP3A5, regulating its expression in endothelial cells. This established what the authors describe as a novel GATA6/CYP3A5/VEGF axis in the tumor-associated endothelium, a signaling cascade that links a nuclear regulator to an enzyme and ultimately to vascular endothelial growth factor, one of the most potent drivers of angiogenesis and immune suppression in cancer.

The single-cell and spatial analyses added another crucial piece to the puzzle: an enrichment of VEGFA–FLT1 signaling between the epithelial cancer cells and the endothelial compartment. This ligand-receptor conversation between tumor and vessel is a hallmark of the tumor microenvironment’s immunosuppressive wiring. Vascular endothelial growth factor is well known to inhibit T cell function and to promote the infiltration of regulatory T cells, the immune system’s own brakes. By mapping this axis with cellular resolution, the study clarified exactly where a therapeutic intervention could intervene to break the circuit.

Enter diosmetin, a natural flavonoid found in citrus fruits and certain medicinal herbs, which has previously shown anti-tumor properties but whose mechanism of action remained murky. The team’s bioinformatic screen flagged CYP3A5 as a functional target associated with diosmetin response. When the researchers tested this experimentally, they found something subtle and important: diosmetin inhibited the enzymatic activity of CYP3A5 without significantly altering the amount of the enzyme the cells produced. In other words, the flavonoid appears to act on the function of the enzyme rather than its abundance, suggesting that CYP3A5 may serve as a functional mediator of diosmetin’s activity in lung adenocarcinoma. The authors are careful to note that further biochemical studies will be required to confirm a direct physical interaction between diosmetin and CYP3A5, a caveat that reflects the rigor of the work.

The functional consequences of this intervention were striking. When endothelial cells were treated with diosmetin and then co-cultured with lung adenocarcinoma cells, the cancer cells lost much of their capacity to proliferate, migrate, and invade, the three behaviors that make tumors deadly. Enzyme-linked immunosorbent assays and Western blotting revealed that the treated endothelial cells also secreted fewer immunosuppressive cytokines, the chemical signals that tell patrolling immune cells to stand down. The tumor-vessel dialogue, in essence, was being rewritten from a conversation that protects the cancer into one that exposes it.

The story held up in living systems. In a xenograft model, diosmetin suppressed tumor growth and angiogenesis, and the treated tumors showed a measurable shift in their immune microenvironment. Because vascular endothelial growth factor is known to disable T cells and recruit regulatory T cells, the authors argue that suppressing endothelial CYP3A5 activity and the VEGF production it drives effectively disrupts an immune-evasive circuit. The dual action is what makes the finding conceptually exciting: a single intervention aimed at an endothelial enzyme simultaneously starves the tumor of new blood vessels and strips away one of its principal shields against immune attack. The researchers do acknowledge an important limitation, however, noting that further studies are needed to validate the immune-related effects in immune-competent models, since xenografts cannot fully recapitulate a functioning immune system.

The translational implications are considerable. Anti-VEGF therapies such as bevacizumab are already part of the standard arsenal against lung cancer, but they come with vascular toxicities and resistance mechanisms. Targeting CYP3A5 enzymatic activity upstream of VEGF offers a different point of entry into the same pathway, one that could theoretically complement existing angiogenesis inhibitors and immune checkpoint blockade. The fact that CYP3A5 expression was most prominent in minimally invasive adenocarcinoma also raises the intriguing possibility of early intervention, a window in which remodeling the endothelial microenvironment might prevent progression to fully invasive disease. And because diosmetin is a dietary flavonoid with a long history of human exposure, it provides a chemical starting point that is already amenable to medicinal chemistry optimization.

None of this means a diosmetin-based drug will reach patients tomorrow. The study is an early, mechanistic proof of concept, built on cell culture, omics data, and xenografts, and the authors themselves flag the need for direct binding studies and immune-competent validation. But the work does something scientifically valuable: it elevates an overlooked endothelial enzyme into a candidate vulnerability, connects it to a master transcriptional regulator, and traces a complete path from GATA6 through CYP3A5 to VEGF and the immunosuppressive microenvironment it creates. In doing so, it reframes the tumor vasculature not merely as a target for blood supply blockade but as an active immune gatekeeper whose enzymatic machinery can, in principle, be turned against the cancer it serves.

Subject of Research: Targeting endothelial CYP3A5 to remodel the immunosuppressive tumor microenvironment in lung adenocarcinoma

Article Title: Targeting endothelial CYP3A5 in lung adenocarcinoma remodels the immunosuppressive microenvironment via VEGF inhibition: Mechanistic insights from Diosmetin

Article References: Cui, D., Yang, Y., Chen, M., Feng, Y., Zhang, W., Zhou, X., & Qiu, R. (2026). Targeting endothelial CYP3A5 in lung adenocarcinoma remodels the immunosuppressive microenvironment via VEGF inhibition: Mechanistic insights from Diosmetin. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04538-1

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04538-1

Keywords: CYP3A5, lung adenocarcinoma, diosmetin, tumor endothelium, VEGF, immunosuppressive microenvironment, GATA6, angiogenesis, cytochrome P450, tumor microenvironment, cancer immunotherapy, flavonoid

The research effort was led by Ilkyu Park, Jae-Ghi Lee, and Jisup Kim, who contributed equally to the work, under the corresponding authorship of Jung Ho Kim at Gachon University Gil Medical Center in Incheon. Rather than relying on bulk sequencing, which averages molecular signals across large chunks of tissue and destroys the crucial architectural context in which cells operate, the team embraced a dual-platform strategy. GeoMx Digital Spatial Profiling allowed them to measure gene expression across precisely annotated regions of interest, while CosMx Spatial Molecular Imaging delivered single-cell and subcellular resolution across hundreds of fields of view. Together, these technologies enabled the researchers to observe not merely which genes were active, but exactly where in the tissue those genes were being switched on and which neighboring cells were talking to one another.

The scale of the study is one of its distinguishing strengths. The investigators analyzed tissue from 89 colorectal cancer patients across 288 carefully annotated regions, encompassing tumor compartments, adjacent normal mucosa, stromal zones, and adipose tissue. They then validated and extended their observations in an independent cohort of 24 patients, evenly split between 12 individuals with obesity and 12 without, spanning 969 individual fields of view. This depth of sampling across both pre-neoplastic and tumor states allowed the team to trace molecular trajectories through time, comparing obese-normal mucosa, non-obese-normal mucosa, tumors from patients with obesity, and tumors from patients without obesity, using formalin-fixed paraffin-embedded clinical specimens that reflect real-world pathology practice.

The first major discovery emerged from an unexpected place: tissue that looked perfectly healthy under the microscope. In the normal-appearing mucosa of patients with obesity, the researchers identified a transcriptionally shifted epithelial state, meaning the genes expressed by the intestinal lining cells had already drifted into a different program even though the tissue retained its normal morphology. Within this obese-normal tissue, the team detected two distinct expression trajectories among a set of 30 genes linked to colorectal cancer. Crucially, a subset of these genes displayed early transcriptional alterations in the obese-normal tissue that were maintained all the way through tumor development. In other words, obesity appears to imprint a molecular signature on the gut epithelium before any visible lesion arises, and that signature persists as cancer takes hold, functioning as a kind of molecular breadcrumb trail from healthy tissue to malignancy.

This pre-neoplastic reprogramming carries significant implications for how scientists think about cancer initiation. The conventional view of carcinogenesis often centers on mutations accumulating over decades, but this work suggests that the systemic metabolic environment created by obesity can push epithelial cells into altered transcriptional states long before genetic damage is fully manifest in tissue architecture. Pathways related to epithelial identity and metabolic reprogramming, including signatures consistent with shifts in processes such as the pentose phosphate pathway and epithelial-mesenchymal transition programs, appear to be engaged in this early phase. If the epithelial lining of a person with obesity is already operating under a different gene-expression regime, interventions aimed at preventing colorectal cancer in this population may need to begin earlier and target these early transcriptional changes rather than waiting for polyps or tumors to appear.

The second phase of the obesity-driven reprogramming unfolds within the tumor itself, and it is immunological in nature. As tumors progressed in patients with obesity, the spatial organization of immune cells inside the tumor microenvironment changed in a distinctly unfavorable direction. The researchers documented a localized enrichment of macrophages expressing SPP1, a gene encoding the secreted protein osteopontin that has been implicated in tumor progression, metastasis, and immune evasion across multiple cancer types. These SPP1-positive macrophages were not scattered uniformly through the tissue; instead, they accumulated in specific spatial niches, clustering near cancer cells where their positioning could most effectively shape tumor behavior.

Even more telling was the ratio shift the team observed. In obese tumors, the balance between SPP1-positive macrophages and pro-inflammatory macrophages changed in favor of the SPP1-positive population, particularly in the regions immediately adjacent to cancer cells. At the same time, the spatial analysis revealed enhanced growth-factor and cytokine-mediated signaling emanating from these localized immune niches. This pattern describes a form of spatially restricted immunosuppression: rather than a wholesale depletion of immune cells, obesity appears to redistribute the immune landscape so that pro-tumor, tissue-remodeling macrophage states dominate the critical interfaces where tumors and immune defenses meet. Such remodeling could help explain clinical observations that obesity-associated colorectal cancers often behave more aggressively and respond differently to immunotherapy than tumors arising in patients of normal weight.

Synthesizing these observations, the authors propose a two-phase model of obesity-driven colorectal carcinogenesis. In the first phase, obesity induces early epithelial transcriptional reprogramming in morphologically intact mucosa, priming the tissue for transformation. In the second phase, once tumors have formed, obesity fosters spatially constrained immunosuppressive remodeling, concentrating SPP1-positive macrophages and pro-tumor signaling at the tumor-immune frontier. The two phases are complementary: an epithelium already nudged toward a cancer-prone transcriptional state faces a tumor microenvironment that has been simultaneously engineered to suppress the immune responses that might otherwise eliminate emerging malignant cells. This dual mechanism reframes obesity not simply as a statistical risk factor but as an active biological agent that rewrites both the target tissue and its defensive ecosystem.

The technical achievement underlying these conclusions deserves emphasis, because it illustrates why spatial transcriptomics has become one of the most transformative tools in modern cancer biology. Traditional single-cell RNA sequencing requires dissociating tissue, losing the spatial coordinates that define how cells actually interact in the body. The GeoMx and CosMx platforms used in this study preserved those coordinates, allowing the researchers to interrogate tumor cores, invasive margins, stromal compartments, adipose depots, and normal mucosa within the same specimens. The identification of cell-cell interaction networks, immune composition shifts, and expression trajectories would have been impossible with dissociative methods, and the concordance of findings across two independent platforms and two patient cohorts strengthens the reliability of the results considerably.

Clinically, the study opens several concrete avenues. The early epithelial gene-expression signature identified in obese-normal mucosa could serve as the basis for biomarker panels that stratify colorectal cancer risk in patients with obesity, potentially guiding the timing and intensity of colonoscopy surveillance. The spatially defined enrichment of SPP1-positive macrophages suggests a specific, targetable node in the immunosuppressive architecture of obesity-associated tumors; therapies designed to deplete, repolarize, or block the recruitment of this macrophage subset could restore anti-tumor immunity where it matters most. Moreover, because the macrophage remodeling is spatially restricted, combinatorial approaches that pair such targeted interventions with existing checkpoint inhibitor immunotherapies may prove particularly effective for this patient population. The work was supported by the National Research Foundation of Korea and approved by the institutional review board at Gachon University Gil Medical Center, with written informed consent obtained from all participants.

As obesity rates continue to climb worldwide and colorectal cancer incidence rises in younger populations, understanding the mechanistic links between the two has become a global health priority. This study demonstrates that the damage inflicted by obesity on colorectal tissue is not a late consequence of established disease but an early, detectable, and spatially organized process that unfolds across years of tumor evolution. By mapping that process at unprecedented resolution, the researchers have transformed obesity from a crude demographic risk marker into a set of actionable molecular and cellular targets, offering new hope that the elevated cancer burden carried by patients with obesity can one day be anticipated, intercepted, and treated with far greater precision than is possible today.

Subject of Research: Obesity-driven spatial reprogramming of the epithelial and immune ecosystem in colorectal cancer

Article Title: Obesity reprograms the spatial ecosystem of colorectal cancer through early epithelial reprogramming and immunosuppressive remodeling

Article References: Park, I., Lee, J.-G., Kim, J., Kim, S.-H., Nam, S., Lee, W.-S., Lee, H., Jang, Y., Chung, J.-W., Kim, K. O., Kwon, K. A., & Kim, J. H. (2026). Obesity reprograms the spatial ecosystem of colorectal cancer through early epithelial reprogramming and immunosuppressive remodeling. Genome Medicine. https://doi.org/10.1186/s13073-026-01758-z

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01758-z

Keywords: colorectal cancer, obesity, spatial transcriptomics, tumor microenvironment, epithelial reprogramming, SPP1 macrophages, immunosuppression, immune remodeling, cancer risk, Genome Medicine, immunotherapy, risk stratification

Liver metastases occupy a uniquely punishing position in the natural history of breast cancer. While modern HER2-targeted therapies—starting with trastuzumab and extending through pertuzumab, lapatinib, tucatinib and trastuzumab deruxtecan—have transformed median survival for HER2-positive disease overall, patients whose cancer has seeded the liver have consistently fared worse than those with metastatic disease confined to other sites. The liver’s dual blood supply, immunosuppressive microenvironment and frequent involvement in drug-resistant clones all contribute to poorer responses to systemic therapy. For this reason, the liver has long been regarded as a sanctuary-like site where conventional regimens lose much of their effectiveness, and the demonstration that a novel agent can meaningfully alter outcomes specifically in this subgroup carries implications well beyond a routine incremental advance.

Disitamab vedotin, also known by its development code RC48, belongs to a class of therapeutics that has become one of the most active frontiers in oncology: the antibody–drug conjugate, or ADC. These molecules are engineered to combine the targeting specificity of a monoclonal antibody with the cell-killing potency of a cytotoxic payload, linked through a chemical connector designed to remain stable in circulation but cleavable once the construct reaches the tumor. Disitamab vedotin pairs a humanized anti-HER2 antibody, disitamab, with monomethyl auristatin E (MMAE), a synthetic analog of molecules derived from marine shellfish toxins that disrupts microtubule assembly and drives apoptotic cell death during cell division. The antibody is conjugated to the payload through a valine-citrulline linker that is cleaved by cathepsin B, a protease enriched in lysosomes, releasing MMAE preferentially within HER2-expressing tumor cells.

What distinguishes disitamab vedotin from earlier ADCs built on the same general blueprint is its drug-to-antibody ratio and its binding characteristics. The conjugation chemistry yields an average of approximately four MMAE molecules per antibody, a higher degree of drug loading than the roughly three-to-four achieved by first-generation breast cancer ADCs but achieved with a more homogeneous attachment strategy that reduces batch-to-batch variability. The antibody itself recognizes a distinct epitope on the extracellular domain of HER2 compared with trastuzumab, which may allow the drug to bind tumor cells even when HER2 expression levels or conformations have shifted under the pressure of prior anti-HER2 treatment. Once internalized, each antibody can deliver a concentrated cytotoxic payload, and a degree of bystander killing—release of membrane-permeable MMAE that diffuses to neighboring tumor cells regardless of their own HER2 density—adds a second layer of antitumor activity. This bystander effect is considered particularly valuable in heterogeneous tumors, where patches of low-HER2 cells can otherwise survive selective pressure and seed resistance.

The RC48-C006 study was designed as a phase 2/3 program, with the pivotal phase 3 portion enrolling patients with HER2-positive breast cancer and liver metastases who had progressed on prior lines of systemic therapy. Participants were randomized to receive disitamab vedotin or comparator chemotherapy, and the trial measured objective response rate and progression-free survival as its primary efficacy endpoints, alongside overall survival and safety. In the reported results, patients treated with disitamab vedotin achieved markedly higher response rates than those receiving standard chemotherapy, with a substantial fraction of tumors shrinking measurably on imaging. Progression-free survival, the time patients live without their disease worsening, was significantly extended, and early overall survival signals pointed in the same direction. The magnitude of benefit in a liver-dominant population—a setting in which even modern regimens often struggle—is the most consequential aspect of the data.

Safety findings tracked the established profile of MMAE-based ADCs. The most commonly observed adverse events included reductions in white blood cell counts, peripheral sensory neuropathy manifested as numbness or tingling in the hands and feet, elevated liver enzymes, hair loss, and gastrointestinal symptoms such as nausea. These toxicities were predominantly manageable with dose modification and supportive care, and the rate of treatment discontinuation due to adverse events remained at a level consistent with clinical practice. Interstitial lung disease, the feared complication associated with some newer ADC platforms, was monitored closely and appeared uncommon in this program. The investigators emphasize that the risk–benefit calculus in a population with few remaining options weighs favorably toward active treatment, though they note that neuropathy in particular warrants proactive monitoring in longer-term survivors.

The significance of the trial extends to its patient selection strategy. HER2 positivity in breast cancer is defined by immunohistochemistry and in situ hybridization testing, and disitamab vedotin has shown activity across a range of HER2 expression levels in earlier studies, including tumors classified as HER2-low. By focusing the phase 3 on unequivocally HER2-positive disease with liver involvement, the investigators targeted the population with the highest unmet need and the clearest biological rationale. The stratification by metastatic site also adds analytic power: rather than enrolling a mixed metastatic population in which liver metastases form a small, underpowered subgroup, RC48-C006 was built from the ground up to answer the question of whether the drug works in this specific, difficult setting. That design choice, still relatively rare in oncology trials, allows the findings to be translated directly into clinical decision-making for patients whose imaging shows hepatic disease.

The mechanistic story underlying the results is one of targeted delivery amplifying an old chemotherapy. MMAE belongs to the auristatin family, molecules that bind tubulin at the vinca alkaloid site and block polymerization into microtubules, the structural scaffolds that cells require to divide. Free MMAE is far too toxic for systemic administration, which is precisely why conjugation to an antibody matters. The therapeutic window emerges from differential exposure: tumor cells that overexpress HER2 internalize hundreds of thousands to millions of antibody molecules per cell, concentrating the payload where it is needed, while circulating antibody largely spares normal tissues that express little or no HER2. Some HER2 is present on cardiac muscle cells, which is why HER2-targeted agents historically raised cardiotoxicity concerns, but the cardiac monitoring in this trial reflected acceptable cardiac safety, consistent with the lower rate of cardiotoxicity seen with ADC platforms compared with prolonged trastuzumab-based blockade.

The results arrive at a moment of intense competition and collaboration in the HER2-directed ADC field, as drugs such as trastuzumab deruxtecan have already demonstrated that payload delivery through HER2 targeting can overcome resistance to older therapies. Disitamab vedotin’s contribution is to extend that paradigm with a distinct antibody, linker and payload combination, and to validate it in a population—HER2-positive disease with liver metastases—where head-to-head level 1 evidence has been scarce. Beyond breast cancer, the agent has been investigated in urothelial carcinoma, gastric cancer and other HER2-expressing tumors, and regulatory approvals in parts of Asia have already been based on earlier-phase evidence. The phase 3 data in liver-metastatic breast cancer now give the drug its strongest evidentiary foundation to date and are likely to inform discussions with regulatory agencies in additional jurisdictions.

For patients and clinicians, the immediate question is sequencing: where disitamab vedotin fits among trastuzumab deruxtecan, tucatinib combinations and other options in the expanding HER2-positive arsenal. Cross-trial comparisons are notoriously unreliable, and the investigators and independent commentators alike caution that only randomized head-to-head studies can determine optimal ordering of the newer agents. What RC48-C006 establishes is that liver metastases need not consign patients to uniformly inferior outcomes, and that an ADC engineered with a Chinese-developed antibody, a protease-cleavable linker and a microtubule-disrupting payload can deliver clinically meaningful benefit precisely where the disease is most resistant. As follow-up matures and overall survival data accumulate, the trial is expected to serve as a reference point for the next generation of studies aimed at the metastatic sites where breast cancer still claims its greatest toll. The study, authored by Wang, Ouyang, Xie and colleagues, was published in Nature Communications in 2026.

Researchers have pioneered a syngeneic mouse teratoma model derived from noncancerous mouse embryonic stem cells (ESCs), marking a significant departure from conventional models reliant on transformed cells. This innovation allows the tracing of tumor evolution in an immunocompetent context from inception, providing an unprecedented window into the earliest immunoediting events as tumors evolve mechanisms to sidestep immune elimination. Using this model, the team executed a genome-wide CRISPR screen to identify genes that influence these nascent phases of tumor-immune interaction, illuminating new molecular players and pathways implicated in immune evasion.

One of the most compelling findings from this screen was that loss of key pro-apoptotic tumor suppressor genes, including the well-known Trp53, paradoxically fostered an alternative cell death modality: necrosis. Unlike apoptosis, which is immunologically silent or even tolerogenic, necrosis is characterized by cell rupture and release of intracellular contents, which can profoundly impact the tumor microenvironment. In this context, necrosis in teratomas induced by Trp53 inactivation led to the abundant release of APOE-enriched lipid particles into the extracellular milieu, a surprisingly potent factor that modulated immune cell behavior within the tumor.

The study revealed that infiltrating T cells, normally potent agents of immune control, were attracted to areas of tumor necrosis but subsequently became dysfunctional after accumulating these APOE-associated lipids. This state of lipid-induced T cell dysfunction unveils a hitherto unrecognized axis of immune evasion where the tumor co-opts necrosis not just as a destructive force but as a biochemical weapon to suppress anti-tumor immunity. The lipid accumulation led to a profound impairment of T cell effector functions, allowing the tumor to escape immune-mediated eradication.

Crucially, the research team demonstrated that disrupting this harmful lipid uptake by T cells rescued their functionality and restored robust immunosurveillance. By either blocking lipid receptor pathways responsible for APOE uptake or mitigating tumor necrosis through inactivation of the mitochondrial permeability transition pore (mPTP) — a key regulator of necrotic cell death — they were able to reverse T cell dysfunction and potentiate immune-mediated tumor control in their mouse model. This two-pronged approach highlights the therapeutic potential of targeting necrosis-induced immunosuppression.

The mitochondrial permeability transition pore (mPTP) is a critical gatekeeper of cell fate, controlling mitochondrial membrane permeability and, when dysregulated, triggering necrosis. Its role in mediating tumor necrosis and subsequent lipid release outlines a novel therapeutic target that bridges cell death pathways and immune modulation. The ability to pharmacologically or genetically inhibit mPTP function in tumor cells to reduce necrosis and lipid release opens new avenues for restoring immune competence in the tumor microenvironment.

Given that mouse teratomas in this model were enriched for brain-like tissues, the investigators extended their inquiry to human glioblastoma multiforme (GBM), a notoriously aggressive brain cancer with poor prognosis and limited therapeutic options. Examination of human GBM tissues revealed a striking parallel: tumors harboring TP53 mutations exhibited regions of necrosis where infiltrating T cells similarly accumulated APOE-laden lipids and were functionally impaired, implicating the same lipid-mediated immune suppression mechanism in human disease.

This discovery in human GBM underscores the translational relevance of the findings from the mouse teratoma model. GBM’s characteristic heterogeneity and immunosuppressive environment have severely hindered effective immunotherapy approaches to date. By identifying lipid accumulation within T cells as a critical axis of suppression linked to tumor necrosis and TP53 loss, the study offers a mechanistic insight into why GBM tumors can so effectively evade immune destruction despite the presence of tumor-infiltrating lymphocytes.

Importantly, the study tested therapeutic interventions targeting this novel immune escape pathway in preclinical GBM models. Treatment with antibodies against APOE—neutralizing the lipid particles—and anti-PDCD1 (anti-PD1), a checkpoint inhibitor reinvigorating T cell activity, produced synergistic enhancement of antitumor immune responses. This combination therapy not only restored T cell function but also significantly prolonged survival in mice bearing GBM tumors, a powerful proof-of-concept for dual targeting of necrosis-induced lipid immunosuppression alongside classical immune checkpoint pathways.

The synergy between anti-APOE and anti-PDCD1 treatment suggests that lipid-mediated immune dysfunction and checkpoint inhibition operate through complementary mechanisms to dampen anti-tumor immunity. Thus, intercepting both arms may overcome the entrenched immunosuppression characteristic of GBM and possibly other tumors with extensive necrotic microenvironments. This represents a paradigm shift in cancer immunotherapy—a move beyond targeting only immune checkpoints toward also modulating the biochemical milieu imposed by tumor cell death.

On a broader level, this study contributes to a growing recognition that tumor cell death modalities profoundly influence immune responses within the tumor microenvironment. Apoptosis and necrosis differentially shape immune cell recruitment, activation, and function, and this work reveals how necrosis-associated lipid release serves as an unexpected but potent immune suppressive mechanism. Further exploration of the myriad ways in which tumor metabolism and cell death converge to sculpt immune evasion will be crucial for the design of next-generation immunotherapies.

Moreover, this research underscores the value of innovative animal models that capture early tumorigenesis and immunoediting dynamics. The syngeneic teratoma model developed herein, derived from embryonic stem cells rather than established tumor lines, enables studies on how cancers initiate immune escape strategies. Such models are indispensable for unraveling the complexities of tumor-immune co-evolution and for preclinical evaluation of immunomodulatory therapies targeting early events rather than late-stage, immune-edited malignancies.

From a clinical standpoint, the identification of APOE lipid particles as modulators of T cell function raises intriguing possibilities for biomarker development. Measuring levels of APOE or lipid accumulation in tumor-infiltrating lymphocytes could serve as indicators of immune dysfunction and guide patient selection for therapies targeting lipid uptake pathways. Furthermore, drugs designed to inhibit lipid receptors on immune cells, in combination with checkpoint inhibitors, may represent a new therapeutic frontier for solid tumors exhibiting necrosis and immunosuppression.

In sum, this landmark study elucidates a novel mechanism of tumor immune evasion centered on necrosis-induced APOE lipid release and T cell lipid accumulation, linking mitochondrial pore-mediated tumor necrosis to functional impairment of infiltrating immune cells. By uncovering this pathway and demonstrating effective therapeutic interventions in glioblastoma models, it lays the groundwork for transforming our approach to immunotherapy in this devastating disease and potentially others defined by necrotic tumor microenvironments.

As the field moves forward, integrating metabolic, cell death, and immune regulatory pathways will be critical to overcome the entrenched resistance mechanisms tumors deploy. This study marks a crucial stride in that direction, revealing new therapeutic vulnerabilities and inspiring hope for more effective immunotherapies against cancers long considered immunologically “cold.” With continued research and clinical translation, targeting necrosis-associated lipid-mediated immune dysfunction could inaugurate a new dawn in cancer treatment.

Subject of Research: Tumor immune evasion mechanisms; early tumor immunoediting; lipid-mediated T cell dysfunction; cancer immunotherapy; glioblastoma immunology; mitochondrial permeability transition pore in tumor necrosis.

Article Title: Targeting necrotic lipid release in tumors enhances immunosurveillance and cancer immunotherapy of glioblastoma.

Article References:
Ji, Y., Jiang, J., Hu, L. et al. Targeting necrotic lipid release in tumors enhances immunosurveillance and cancer immunotherapy of glioblastoma. Cell Res (2025). https://doi.org/10.1038/s41422-025-01155-y

Image Credits: AI Generated

Traditionally regarded as a lymphoid organ primarily involved in blood filtration and immune surveillance, the spleen has long been underestimated for its regenerative potential. The research team, led by Professors Lei Dong and Jian Xiao, challenged this dogma by engineering a microenvironment within the spleen that supports not only cell survival but also functional maturation of transplanted human islets. This approach circumvents two critical obstacles that have historically limited the success of islet transplantation: poor cell survival due to inadequate extracellular support and immune-mediated graft rejection.

At the core of their innovation lies the deployment of sophisticated immunomodulatory nanoparticles designed to reprogram the spleen’s microenvironment. These nanoparticles enhance the extracellular matrix, promote angiogenesis, and create an immunosuppressive milieu, which collectively orchestrate a niche conducive to islet engraftment and functionality. By modifying the spleen’s local immune responses and tissue architecture, the researchers converted this once overlooked organ into a bioengineered hub where transplanted cells can not only survive but integrate and proliferate.

This reprogramming effort facilitated the survival and functional maturation of human islet tissues inside the spleens of cynomolgus macaques, non-human primates that serve as an essential preclinical model. Remarkably, the spleen exhibited compatibility with both xenogeneic (human) and allogeneic (animal) cell sources, underscoring the platform’s versatility and its potential to address organ shortages through cross-species transplantation strategies. This breakthrough signals a new paradigm, wherein the spleen is utilized as a living factory to cultivate organ-specific cells within the host, minimizing the complications associated with external organ transplantation.

The biological rationale for selecting the spleen is rooted in its intrinsic characteristics. Its porous and spacious architecture can accommodate billions of cells, providing a structurally supportive scaffold. Moreover, the spleen’s direct blood flow into the liver’s portal vein system offers a nutrient-rich, physiologically relevant environment akin to natural developmental settings for islet cells. Finally, the organ’s capacity to undergo remodeling without compromising systemic homeostasis makes it an ideal candidate for repeated therapeutic interventions.

The research is not an isolated achievement but the continuation of a series of pioneering studies by the team. Earlier work demonstrated that mouse spleens could be reprogrammed to assume liver functions, exemplified in their 2020 Science Advances publication. Subsequently, in 2022, they successfully grew liver tissues in situ using gene-editing technologies, bypassing the need for exogenous cell transplantation. More recently, they rebuilt hormone-secreting thyroid tissues within animal spleens, showcasing the platform’s adaptability for diverse organ systems. This cumulative evidence solidifies the spleen’s role as a multi-organ regeneration factory within the mammalian body.

Looking forward, the investigators are exploring the integration of induced pluripotent stem cells (iPSCs) into their spleen bioreactor model to realize patient-specific organogenesis. This strategy envisages harvesting a patient’s own reprogrammed stem cells, delivering them via minimally invasive ultrasound-guided techniques into the spleen, and nurturing fully functional organs tailored to the individual’s immunological profile. Such personalized regenerative therapy could obviate lifelong immunosuppression and dramatically elevate transplant success rates.

Clinically, the transition from experimental models to human applications will necessitate a stringent evaluation of biosafety, efficacy, and long-term functional outcomes. Immune tolerance, potential off-target effects of nanoparticle delivery, and sustained organ performance remain pivotal challenges to address. Nevertheless, this research fundamentally challenges prior assumptions about the spleen’s dispensability and harnesses its latent potential to redefine the future landscape of organ replacement therapies.

Professors Dong and Xiao’s vision encapsulates a transformative concept of the spleen—not just as an immune organ but as a versatile bioreactor embedded within the human body, silently manufacturing life-saving tissues on demand. Their method converges advanced nanotechnology, tissue engineering, and immunology in a highly sophisticated platform that could eventually eliminate the organ shortage crisis and revolutionize treatment options for diabetics and patients with organ failure worldwide.

This emerging paradigm aligns with the broader goals of regenerative medicine: to create endogenous platforms where damaged or deficient tissues are repaired or replaced within the patient’s own body, thereby reducing complications from immunorejection and improving quality of life. This study exemplifies the power of interdisciplinary collaboration and innovation, shining a new light on an organ once believed secondary but now revealed as a cornerstone for future regenerative therapies.

The scientific community and healthcare providers alike will watch closely as this research continues to evolve, with anticipation that it will catalyze a wave of organ bioengineering advances. The spleen, a long-overlooked player in systemic physiology, now stands at the cusp of transforming not only how we understand organogenesis but also how medicine approaches tissue failure, heralding a future where bespoke, in-body organ factories become a clinical reality.

Subject of Research: Animals

Article Title: Islet transplantation in immunomodulatory nanoparticle–remodeled spleens

News Publication Date: 21-May-2025

Web References: http://dx.doi.org/10.1126/scitranslmed.adj9615

Image Credits: Credited by Lei Dong/Nanjing University and Jian Xiao/Wenzhou Medical University

Keywords: Cell biology

Ovarian cancer poses a formidable clinical challenge, partly due to its silent progression and the fact that over seventy percent of cases are diagnosed at advanced stages. A hallmark of these late-stage cases is the accumulation of large volumes of ascites—an abnormal buildup of fluid within the peritoneal cavity. Beyond serving as a medium for physical tumor dissemination, this ascites fluid creates a biochemically hostile milieu that sabotages immune surveillance and effector functions. Understanding the intricate interplay between ascites and immune cell dynamics has thus become a paramount objective in cancer immunology research.

The study, conducted collaboratively by Trinity College Dublin and University College Dublin, focused intensively on key immune effector cells: natural killer (NK) cells and T lymphocytes. Both cell types play vital roles in orchestrating anti-cancer immunity through their capacity to recognize and destroy malignant cells. However, in the context of ovarian cancer-associated ascites, the functionality of these lymphocytes appears compromised. By employing state-of-the-art biochemical assays and cellular immunophenotyping techniques, researchers sought to decipher the molecular culprits within the ascitic fluid responsible for this immune paralysis.

Detailed lipidomic analyses of ascitic fluid samples revealed a preponderance of specific phospholipids—complex lipid molecules integral to cell membranes and signaling pathways. These phospholipids emerged as pivotal mediators of immune dysfunction, exhibiting the capacity to infiltrate NK cells and disrupt their metabolic homeostasis. Such interference alters the bioenergetics and effector programming of NK cells, culminating in diminished cytotoxic activity against ovarian tumor cells. This modulation of NK cell metabolism by phospholipids represents a previously unappreciated axis of tumor-mediated immune evasion.

Dr. Karen Slattery, Research Fellow at the Trinity Translational Medicine Institute and the study’s lead author, elaborated on these findings: “Our data demonstrate that phospholipid uptake into NK cells is a critical event leading to immune suppression. By blocking this uptake pathway with a targeted receptor inhibitor, we were able to restore NK cells’ ability to effectively target and kill ovarian cancer cells in vitro. This receptor blockade represents a novel therapeutic avenue to reinvigorate immune responses suppressed by the lipid-rich ascitic environment.”

This paradigm-shifting discovery provides a mechanistic explanation for the aggressive nature and poor prognostic outcomes often associated with advanced ovarian cancer. Despite the immune system’s inherent capacity to detect and eliminate cancer cells, the hostile lipid-dominated microenvironment within ascites forcibly switches off this critical defense mechanism. Unraveling the biochemical and immunometabolic barriers imposed by tumor-associated lipids offers researchers and clinicians an opportunity to counteract this immune suppression therapeutically.

Professor Lydia Lynch, senior author and immunologist formerly at Trinity College and currently at Princeton University, underscored the clinical implications: “This study fundamentally advances our understanding by identifying fat-derived immunosuppressive molecules as obstacles to effective anti-tumor immunity in ovarian cancer patients. Targeting these molecules or their associated metabolic pathways has the potential to restore immune competence, enabling the body’s natural defenses to combat tumor progression more effectively.”

Ascites fluid has long been recognized not only as a symptom but as a facilitator of ovarian cancer dissemination and peritoneal metastasis. However, its role as a biochemical barrier to immune function has only recently been appreciated in molecular detail. The findings from this research suggest that phospholipids within the ascitic milieu actively subvert NK and possibly T cell metabolic programming—a prerequisite for their anti-tumor cytotoxicity.

The immune suppressive effects induced by ascitic phospholipids invoke changes in key metabolic regulators inside NK cells, including alterations to glycolytic flux and mitochondrial function. Since energy metabolism underpins immune cell activation and effector function, such metabolic derangements effectively ‘disarm’ these immune sentinels. By focusing on metabolic restoration, future therapies might reverse immunosuppression not merely by blocking checkpoint molecules but by reinvigorating cell metabolism.

Furthermore, the identification of specific lipid receptors mediating phospholipid uptake in NK cells opens a previously untapped targetable interface. Inhibitors or blocking antibodies designed to prevent this lipid trafficking could be developed into adjunct immunotherapies. Such precision interventions may synergize with existing immuno-oncology agents, amplifying clinical responses in a cancer subtype notoriously refractory to treatment.

This research vividly illustrates the importance of the tumor microenvironment’s biochemical landscape in modulating immune responses—particularly how aberrant lipid metabolism within ascites fluid shapes immune evasion mechanisms. It pushes the frontiers of cancer immunology by integrating lipidomics and immunometabolism to unravel complex tumor-host interactions.

Ultimately, this work lays the groundwork for a new class of immunotherapeutics tailored to antagonize lipid-induced immune dysfunction in ovarian cancer. As immunotherapies continue to revolutionize cancer treatment paradigms, overcoming metabolic suppression within the tumor microenvironment represents a crucial step forward. The prospect of restoring NK cell function through receptor blockade could significantly enhance immune-mediated tumor clearance and transform patient prognoses.

Given the high mortality associated with advanced ovarian cancer and the limited efficacy of current therapies, these findings inject renewed hope into the clinical landscape. By elucidating a novel metabolic checkpoint controlled by lipid mediators, the study illuminates new biological pathways and therapeutic targets. Future research will focus on validating these targets in clinical trials, optimizing receptor-blocking agents, and integrating metabolic reprogramming into multimodal ovarian cancer treatment strategies.

This transformative body of work exemplifies how cutting-edge translational science can connect tumor biochemistry to immune cell biology, yielding actionable insights. It underscores the critical need to consider metabolic and lipidomic contexts when designing next-generation immunotherapies for ovarian and potentially other solid malignancies characterized by aberrant fluid accumulation and metabolic dysregulation.

Subject of Research: Immune suppression mechanisms in advanced ovarian cancer mediated by lipid-rich ascites.

Article Title: Lipid-Induced Immune Dysfunction in Ovarian Cancer Ascites Impairs Natural Killer Cell Metabolism and Anti-Tumor Activity.

Web References: DOI: 10.1126/sciimmunol.adr4795

Image Credits: Dr Karen Slattery, Trinity College Dublin.

Keywords: Cancer, Ovarian cancer, Medical treatments, Immunotherapy, Cancer immunology